Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular(Wet) Age Related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Testing effectiveness (Phase 2)Study completedNCT04832724
What this trial is testing

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular DegenerationWet Age-related Macular Degeneration
AbbVie 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04514653
What this trial is testing

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 146
Early research (Phase 1)UnknownNCT03675880
What this trial is testing

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

Who this might be right for
AMD
Lee's Pharmaceutical Limited 24
Testing effectiveness (Phase 2)Study completedNCT03066258
What this trial is testing

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Who this might be right for
Neovascular Age-related Macular DegenerationWet Age-related Macular Degeneration
REGENXBIO Inc. 42
Post-approval studies (Phase 4)UnknownNCT00813891
What this trial is testing

Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

Who this might be right for
Macular DegenerationVisual Acuity
McGill University Health Centre/Research Institute of the McGill University Health Centre 180
Testing effectiveness (Phase 2)Study completedNCT03927690
What this trial is testing

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Novartis Pharmaceuticals 91
Post-approval studies (Phase 4)Study completedNCT02441816
What this trial is testing

VITAL - Individualising Therapy for Neovascular AMD With Aflibercept

Who this might be right for
Age Related Macular Degeneration
Moorfields Eye Hospital NHS Foundation Trust 50
Testing effectiveness (Phase 2)UnknownNCT06183814
What this trial is testing

EXG102-031 in Participants With wAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd 42
Not applicableStudy completedNCT07744984
What this trial is testing

The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab

Who this might be right for
Age-Related Macular Degeneration (AMD)Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Rabin Medical Center 12
Early research (Phase 1)WithdrawnNCT02450981
What this trial is testing

Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
Biocad
Large-scale testing (Phase 3)Study completedNCT00090623
What this trial is testing

RhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Genentech, Inc. 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT06550011
What this trial is testing

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Who this might be right for
Neovascular (Wet) AMD
Avirmax Biopharma Inc 18
Early research (Phase 1)Study completedNCT02461771
What this trial is testing

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Apellis Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Ended earlyNCT02418754
What this trial is testing

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals 505
Not applicableActive Not RecruitingNCT07390253
What this trial is testing

Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular (Wet) Age-Related Macular Degeneration
Vienna Institute for Research in Ocular Surgery 50
Early research (Phase 1)Study completedNCT02204683
What this trial is testing

Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

Who this might be right for
Neovascular Macular Degeneration
University of Nebraska 5